Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130404 | 0.93 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1HRH3MBTD1MMP2 | |
| SCHEMBL4125512 | 0.92 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1HRH3MBTD1MMP2 | |
| SCHEMBL4134876 | 0.79 | GRIN2D (0.40) | HRH3 | |
| SCHEMBL2155939 | 0.77 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1KMT2A | |
| SCHEMBL1286823 | 0.76 | USP2 (0.48) | USP2KMT2A | |
| SCHEMBL4125536 | 0.75 | HRH3 (0.47) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4130613 | 0.75 | GRIN2D (0.39) | HRH3 | |
| SCHEMBL4282555 | 0.75 | CHRM1 (0.48) | HRH3 | |
| SCHEMBL4284430 | 0.75 | KDM2B (0.46) | HRH3USP2 | |
| SCHEMBL14027014 | 0.75 | TRIM24 (0.56) | L3MBTL3L3MBTL1HRH3MBTD1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | L3MBTL3 2655/4885L3MBTL1 2620/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.